TNF-ALPHA AND BMP2-WNT SIGNALING IN DIABETIC VASCULAR DISEASE
糖尿病血管疾病中的 TNF-α 和 BMP2-WNT 信号转导
基本信息
- 批准号:8020994
- 负责人:
- 金额:$ 38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-04-15 至 2013-01-31
- 项目状态:已结题
- 来源:
- 关键词:AmputationAnti-Inflammatory AgentsAnti-inflammatoryAortaArteriesBMP2 geneBenignBlood VesselsCalciumCaliberCellsCharacteristicsClinicalComplementControlled StudyCritiquesDactinomycinDataDiabetes MellitusDiabetic AngiopathiesDiabetic macrovascular diseaseDietEpidemicFatty acid glycerol estersFunctional disorderGene ExpressionGenesGeneticGenetic TranscriptionGlomerular CapillaryGoalsHandHealthHealth Care CostsHeartInflammationKidney DiseasesKidney GlomerulusLaboratoriesLeadLife StyleLongevityMMP9 geneManuscriptsMedialMediatingMessenger RNAModelingMolecularMusMuscleMyofibroblastNADPH OxidaseNon-Insulin-Dependent Diabetes MellitusObesityOxidasesOxidation-ReductionOxidative StressPathway interactionsPatientsPhenotypePhysiologyPlethysmographyRecombinantsRecommendationRegulationRetinaRetinalRiskRoleSignal TransductionSocietiesSodium SalicylateStructureStudy modelsSuperoxidesTNF geneTNFRSF11B geneTNFSF11 geneTechniquesTestingTissuesTumor Necrosis Factor-alphaUp-RegulationVascular DiseasesVascular calcificationWNT Signaling Pathwayacetovanilloneattenuationcalcificationcostdiabeticdigitalexperiencefeedingfoothuman TNF proteinimprovedin vivoinfliximabinhibitor/antagonistinsightintraperitonealmacrovascular diseasemortalitynovel strategiesosteogenicpreferencepressurepreventpromoterresearch studyresponsesalicylatevascular inflammation
项目摘要
DESCRIPTION (provided by applicant): Westernized societies are experiencing an epidemic of type II diabetes (T2DM), related to life-style, obesity, and longevity. T2DM is a systemic vascular disorder; wide-spread low grade arterial inflammation, elevated TNF-alpha levels, & oxidative stresses disrupt macrovascular (e.g., heart, aorta) & microvascular (e.g. retina, renal glomerulus) functions. A highly characteristic feature of T2DM is medial artery calcification (MAC). The negative consequences of reduced aortofemoral compliance of MAC have emerged; MAC perturbs normal Windkessel physiology, causing systolic & diastolic dysfunction that increases mortality & amputation risk. The ability to prevent or treat MAC represents an unmet clinical need. A better understanding of how diabetes and kidney disease (CKD) promote MAC will provide insights useful for devising new strategies to reduce vascular calcium load, preserve aortic compliance, & improve vascular function. Recent data have identified activated aortic BMP2-Msx2-Wnt signaling in diabetic MAC--all inhibited by infliximab. The chief goal of this project is to assess how targeting these signals can improve aortic calcification, structure, & compliance. Aim 1: "To test whether inhibition of arterial BMP2- Wnt induction with theTNF-alpha antagonist infliximab or salicylate improves aortic compliance in diabetic vascular disease." By assessing aortic pressure- diameter relationships using ex vivo video plethysmography, we will establish the relationships between TNF-alpha & aortic calcium accumulation, Wnt signaling, and stiffness in a relevant T2DM model--the TOPGAL+; LDLR-/- mouse fed diabetogenic high fat diets (HFD). Comparison will be made with responses to the RANKL inhibitor, OPG. Aim 2: "To characterize the mechanisms whereby TNF- alpha signaling via NADPH oxidase promotes Msx2 gene transcription in aortic adventitial myofibroblasts." The NAPDH oxidase inhibitor, apocynin, inhibits Msx2 induction by TNF-alpha (transcriptionally mediated). By identifying the signaling cascades conveying Msx2 induction in response to TNF-alpha, novel strategies can be devised to inhibit vascular calcification. Aim 3: "To identify if NADPH oxidase signaling is required for induction of aortic BMP2-Msx-2-Wnt cascades in T2DM, using p47phox- /-; TOPGAL+; LDLR-/- mice as a model." By phenotyping p47phox-/-; TOPGAL+; LDLR-/- and p47phox+/-;TOPGAL+; LDLR-/- controls, we assess whether this TNF- regulated redox pathway contributes to aortic BMP2-Msx2-Wnt activation by HFD.
描述(由申请人提供):西方化社会正经历着2型糖尿病(T2DM)的流行,与生活方式、肥胖和寿命有关。T2DM是一种全身性血管疾病;广泛的低级别动脉炎症、tnf - α水平升高和氧化应激破坏大血管(如心脏、主动脉)和微血管(如视网膜、肾小球)功能。T2DM的一个高度特征性特征是内侧动脉钙化(MAC)。MAC降低主动脉股动脉顺应性的负面后果已经出现;MAC扰乱正常的血管生理,引起收缩和舒张功能障碍,增加死亡率和截肢风险。预防或治疗MAC的能力是尚未满足的临床需求。更好地了解糖尿病和肾脏疾病(CKD)如何促进MAC,将为设计减少血管钙负荷、保持主动脉顺应性和改善血管功能的新策略提供有用的见解。最近的数据表明,糖尿病MAC中激活的主动脉BMP2-Msx2-Wnt信号均被英夫利昔单抗抑制。该项目的主要目标是评估如何靶向这些信号来改善主动脉钙化、结构和顺应性。目的1:“测试tnf - α拮抗剂英夫利昔单抗或水杨酸盐是否能抑制动脉BMP2- Wnt诱导,改善糖尿病血管疾病的主动脉顺应性。”通过使用离体视频容积图评估主动脉压力-直径的关系,我们将在相关的T2DM模型中建立tnf - α与主动脉钙积累、Wnt信号和僵硬度之间的关系。LDLR-/-小鼠饲喂致糖尿病性高脂饲料(HFD)。将与RANKL抑制剂OPG的反应进行比较。目的2:“表征TNF- α信号通过NADPH氧化酶促进主动脉内膜肌成纤维细胞中Msx2基因转录的机制。”NAPDH氧化酶抑制剂,apocynin,抑制tnf - α(转录介导)诱导Msx2。通过识别响应tnf - α传递Msx2诱导的信号级联,可以设计新的策略来抑制血管钙化。目的3:“为了确定是否需要NADPH氧化酶信号来诱导T2DM患者主动脉BMP2-Msx-2-Wnt级联,使用p47phox- /-;TOPGAL +;以LDLR-/-小鼠为模型。”通过表型分析p47phox-/-;TOPGAL +;LDLR-/-和p47phox+/-;TOPGAL+;LDLR-/-对照,我们评估这种TNF-调节的氧化还原途径是否有助于HFD激活主动脉BMP2-Msx2-Wnt。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DWIGHT A. TOWLER其他文献
DWIGHT A. TOWLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DWIGHT A. TOWLER', 18)}}的其他基金
Cdc42bpg signaling in arteriosclerosis and vascular fibrosis
动脉硬化和血管纤维化中的 Cdc42bpg 信号传导
- 批准号:
10448070 - 财政年份:2022
- 资助金额:
$ 38万 - 项目类别:
University of Texas Southwestern - Stimulating Access to Research in Residency (UT-StARR) Program
德克萨斯大学西南分校 - 促进住院医师研究 (UT-StARR) 计划
- 批准号:
10655275 - 财政年份:2021
- 资助金额:
$ 38万 - 项目类别:
Endocrine Regulation of Calcific Aortic Valve Sclerosis: PTH/PTHRP Receptor Signa
钙化性主动脉瓣硬化的内分泌调节:PTH/PTHRP 受体信号
- 批准号:
8856647 - 财政年份:2012
- 资助金额:
$ 38万 - 项目类别:
Endocrine Regulation of Calcific Aortic Valve Sclerosis: PTH/PTHRP Receptor Signa
钙化性主动脉瓣硬化的内分泌调节:PTH/PTHRP 受体信号
- 批准号:
8597586 - 财政年份:2012
- 资助金额:
$ 38万 - 项目类别:
Endocrine Regulation of Calcific Aortic Valve Sclerosis: PTH/PTHRP Receptor Signa
钙化性主动脉瓣硬化的内分泌调节:PTH/PTHRP 受体信号
- 批准号:
8535817 - 财政年份:2012
- 资助金额:
$ 38万 - 项目类别:
Endocrine Regulation of Calcific Aortic Valve Sclerosis: PTH/PTHRP Receptor Signa
钙化性主动脉瓣硬化的内分泌调节:PTH/PTHRP 受体信号
- 批准号:
8697129 - 财政年份:2012
- 资助金额:
$ 38万 - 项目类别:
Endocrine Regulation of Calcific Aortic Valve Sclerosis: PTH/PTHRP Receptor Signa
钙化性主动脉瓣硬化的内分泌调节:PTH/PTHRP 受体信号
- 批准号:
8352879 - 财政年份:2012
- 资助金额:
$ 38万 - 项目类别:
TNF-ALPHA AND BMP2-WNT SIGNALING IN DIABETIC VASCULAR DISEASE
糖尿病血管疾病中的 TNF-α 和 BMP2-WNT 信号转导
- 批准号:
7608622 - 财政年份:2008
- 资助金额:
$ 38万 - 项目类别:
TNF-ALPHA AND BMP2-WNT SIGNALING IN DIABETIC VASCULAR DISEASE
糖尿病血管疾病中的 TNF-α 和 BMP2-WNT 信号转导
- 批准号:
7762246 - 财政年份:2008
- 资助金额:
$ 38万 - 项目类别:
TNF-ALPHA AND BMP2-WNT SIGNALING IN DIABETIC VASCULAR DISEASE
糖尿病血管疾病中的 TNF-α 和 BMP2-WNT 信号转导
- 批准号:
7364683 - 财政年份:2008
- 资助金额:
$ 38万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 38万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 38万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 38万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 38万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 38万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 38万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 38万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 38万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 38万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 38万 - 项目类别: